Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

The literature exploring the utility of advanced echocardiographic techniques (such as deformation imaging) in the diagnosis and prognostication of patients receiving potentially cardiotoxic cancer therapy has involved relatively small trials in the research setting. In this systematic review of the current literature, we describe echocardiographic myocardial deformation parameters in 1,504 patients during or after cancer chemotherapy for 3 clinically-relevant scenarios. The systematic review was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines using the EMBASE (1974 to November 2013) and MEDLINE (1946 to November 2013) databases. All studies of early myocardial changes with chemotherapy demonstrate that alterations of myocardial deformation precede significant change in left ventricular ejection fraction (LVEF). Using tissue Doppler-based strain imaging, peak systolic longitudinal strain rate has most consistently detected early myocardial changes during therapy, whereas with speckle tracking echocardiography (STE), peak systolic global longitudinal strain (GLS) appears to be the best measure. A 10% to 15% early reduction in GLS by STE during therapy appears to be the most useful parameter for the prediction of cardiotoxicity, defined as a drop in LVEF or heart failure. In late survivors of cancer, measures of global radial and circumferential strain are consistently abnormal, even in the context of normal LVEF, but their clinical value in predicting subsequent ventricular dysfunction or heart failure has not been explored. Thus, this systematic review confirms the value of echocardiographic myocardial deformation parameters for the early detection of myocardial changes and prediction of cardiotoxicity in patients receiving cancer therapy.

[1]  G. Mantovani,et al.  Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. , 2007, The oncologist.

[2]  C. Gross,et al.  Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. , 2012, Journal of the American College of Cardiology.

[3]  Mario J. Garcia,et al.  Doppler-Derived Myocardial Systolic Strain Rate Is a Strong Index of Left Ventricular Contractility , 2002, Circulation.

[4]  S. Ha,et al.  Left Ventricular Twisting and Untwisting Motion in Childhood Cancer Survivors , 2011, Echocardiography.

[5]  G. Mantovani,et al.  Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. , 2008, The oncologist.

[6]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[7]  T. Marwick,et al.  Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. , 2014, European heart journal cardiovascular Imaging.

[8]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[9]  F. Veglia,et al.  Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[11]  M. Somerfield,et al.  American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Hunt,et al.  Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Helmut Baumgartner,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, European journal of heart failure.

[14]  S. Ha,et al.  Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy , 2010, Heart.

[15]  D. Jassal,et al.  Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study , 2009, Breast Cancer Research and Treatment.

[16]  D. Shen,et al.  Protective Effects of Salidroside on Epirubicin-Induced Early Left Ventricular Regional Systolic Dysfunction in Patients with Breast Cancer , 2012, Drugs in R&D.

[17]  S. Ha,et al.  Transmural strain and rotation gradient in survivors of childhood cancers. , 2013, European heart journal cardiovascular Imaging.

[18]  P. Sengupta,et al.  Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  S. Kutty,et al.  Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[20]  Y. Cheung,et al.  New three-dimensional speckle-tracking echocardiography identifies global impairment of left ventricular mechanics with a high sensitivity in childhood cancer survivors. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[21]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[22]  Ton Feuth,et al.  Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. , 2013, European heart journal cardiovascular Imaging.

[23]  Mohammed A. Al-Biltagi,et al.  Strain Echocardiography in Early Detection of Doxorubicin-Induced Left Ventricular Dysfunction in Children with Acute Lymphoblastic Leukemia , 2012, ISRN pediatrics.

[24]  G. Sutherland,et al.  Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. , 2007, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[25]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[26]  T. Marwick,et al.  Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. , 2013, Journal of the American College of Cardiology.

[27]  K. Byth,et al.  Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. , 2013, European journal of cancer.

[28]  Xiaojun Bi 毕小军,et al.  Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients , 2009, Journal of Huazhong University of Science and Technology [Medical Sciences].

[29]  Pamela S Douglas,et al.  Acc/aha/ase 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines (acc/aha/ase Committee to Update the 1997 Guidelines for the Clinical Application of Echocar , 2003 .

[30]  S. Lippman,et al.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Rademakers,et al.  Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[32]  S. Fosså,et al.  Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. , 2011, The American journal of cardiology.

[33]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[34]  S. Meikle,et al.  Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. , 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[35]  G. Mantovani,et al.  Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. , 2010, American heart journal.

[36]  Victor Mor-Avi,et al.  Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[37]  A. Neugut,et al.  Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Bartelink,et al.  Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. , 2007, Journal of the National Cancer Institute.

[39]  T. Marwick,et al.  Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[40]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[41]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[42]  Ton Feuth,et al.  Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. , 2010, Ultrasound in medicine & biology.

[43]  R. Murphy,et al.  Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study , 2010, Heart.

[44]  T. Marwick,et al.  Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. , 2009, American heart journal.

[45]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[46]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[47]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[48]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[49]  M. Marchese,et al.  Serum Markers, Conventional Doppler Echocardiography and Two-dimensional Systolic Strain in the Diagnosis of Chemotherapy-Induced Myocardial Toxicity , 2013 .

[50]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[51]  Randolph P. Martin,et al.  Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab , 2012, Circulation. Cardiovascular imaging.

[52]  Piet Claus,et al.  Acute cardiac functional and morphological changes after Anthracycline infusions in children. , 2007, The American journal of cardiology.

[53]  A. Varan,et al.  Tissue Doppler and myocardial deformation imaging to detect myocardial dysfunction in pediatric cancer patients treated with high doses of anthracyclines , 2012, Asia-Pacific journal of clinical oncology.

[54]  Krishnaswamy Chandrasekaran,et al.  Twist mechanics of the left ventricle: principles and application. , 2008, JACC. Cardiovascular imaging.

[55]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Lucian Petrescu,et al.  Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. , 2013, Canadian journal of physiology and pharmacology.

[57]  J. Voigt,et al.  Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. , 2013, International Journal of Radiation Oncology, Biology, Physics.

[58]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[59]  Thomas H Marwick,et al.  Normal ranges of left ventricular strain: a meta-analysis. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[60]  Jong Hun Park,et al.  Cardiac Functional Evaluation Using Vector Velocity Imaging After Chemotherapy Including Anthracyclines in Children With Cancer , 2009, Korean circulation journal.

[61]  Randolph P. Martin,et al.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. , 2011, The American journal of cardiology.

[62]  S. Meikle,et al.  Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. , 2013, European heart journal cardiovascular Imaging.

[63]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[64]  R. Nagai,et al.  Anthracycline-induced cardiomyopathies evaluated by tissue Doppler tracking system and strain rate imaging. , 2001, Journal of Cardiology.

[65]  F. Roila,et al.  Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  Jens-Uwe Voigt,et al.  Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. , 2011, International journal of radiation oncology, biology, physics.

[67]  J. Mackey,et al.  Contemporary Reviews in Cardiovascular Medicine Cancer Therapy – Induced Cardiac Toxicity in Early Breast Cancer Addressing the Unresolved Issues , 2012 .

[68]  Pawan K. Singal,et al.  The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. , 2011, Journal of the American College of Cardiology.

[69]  J. Koyama,et al.  Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. , 2012, European heart journal cardiovascular Imaging.

[70]  D. Jassal,et al.  Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[71]  P. Neven,et al.  A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. , 2008, Critical reviews in oncology/hematology.